The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
Barbara P Yawn1, Ibrahim Raphiou2, Judith S Hurley3, Anand A Dalal21Olmsted Medical Center, University of Minnesota, Rochester, Minnesota, USA; 2GlaxoSmithKline, Research Triangle Park, North Carolina, USA; 3Hurley Consulting, Placitas, New Mexico, USAAbstract: Exacerbations contribute significantly...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-06-01
|
| Series: | International Journal of COPD |
| Online Access: | http://www.dovepress.com/the-role-of-fluticasone-propionatesalmeterol-combination-therapy-in-pr-a4535 |
| _version_ | 1811279861699837952 |
|---|---|
| author | Barbara P Yawn Ibrahim Raphiou Judith S Hurley et al |
| author_facet | Barbara P Yawn Ibrahim Raphiou Judith S Hurley et al |
| author_sort | Barbara P Yawn |
| collection | DOAJ |
| description | Barbara P Yawn1, Ibrahim Raphiou2, Judith S Hurley3, Anand A Dalal21Olmsted Medical Center, University of Minnesota, Rochester, Minnesota, USA; 2GlaxoSmithKline, Research Triangle Park, North Carolina, USA; 3Hurley Consulting, Placitas, New Mexico, USAAbstract: Exacerbations contribute significantly to the morbidity of COPD, leading to an accelerated decline in lung function, reduced functional status, reduced health status and quality of life, poorer prognosis and increased mortality. Prevention of exacerbations is thus an important goal of COPD management. In patients with COPD, treatment with a combination of the inhaled corticosteroid fluticasone propionate (250 μg) and the long-acting β2-agonist salmeterol (50 μg) in a single inhaler (250/50 μg) is an effective therapy option that has been shown to reduce the frequency of exacerbations, to improve lung function, dyspnea and health status, and to be relatively cost-effective as a COPD maintenance therapy. Importantly, results of various studies suggest that fluticasone propionate and salmeterol have synergistic effects when administered together that improve their efficacy in controlling symptoms and reducing exacerbations. The present non-systematic review summarizes the role of fluticasone propionate/salmeterol combination therapy in the prevention of exacerbations of COPD and its related effects on lung function, survival, health status, and healthcare costs.Keywords: Advair, COPD, disease exacerbation, fluticasone propionate, salmeterol, combination drug therapy |
| first_indexed | 2024-04-13T01:03:26Z |
| format | Article |
| id | doaj.art-8a7e1b6ecf5145478138e0a01cd33fd9 |
| institution | Directory Open Access Journal |
| issn | 1176-9106 1178-2005 |
| language | English |
| last_indexed | 2024-04-13T01:03:26Z |
| publishDate | 2010-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of COPD |
| spelling | doaj.art-8a7e1b6ecf5145478138e0a01cd33fd92022-12-22T03:09:25ZengDove Medical PressInternational Journal of COPD1176-91061178-20052010-06-012010default165178The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPDBarbara P YawnIbrahim RaphiouJudith S Hurleyet alBarbara P Yawn1, Ibrahim Raphiou2, Judith S Hurley3, Anand A Dalal21Olmsted Medical Center, University of Minnesota, Rochester, Minnesota, USA; 2GlaxoSmithKline, Research Triangle Park, North Carolina, USA; 3Hurley Consulting, Placitas, New Mexico, USAAbstract: Exacerbations contribute significantly to the morbidity of COPD, leading to an accelerated decline in lung function, reduced functional status, reduced health status and quality of life, poorer prognosis and increased mortality. Prevention of exacerbations is thus an important goal of COPD management. In patients with COPD, treatment with a combination of the inhaled corticosteroid fluticasone propionate (250 μg) and the long-acting β2-agonist salmeterol (50 μg) in a single inhaler (250/50 μg) is an effective therapy option that has been shown to reduce the frequency of exacerbations, to improve lung function, dyspnea and health status, and to be relatively cost-effective as a COPD maintenance therapy. Importantly, results of various studies suggest that fluticasone propionate and salmeterol have synergistic effects when administered together that improve their efficacy in controlling symptoms and reducing exacerbations. The present non-systematic review summarizes the role of fluticasone propionate/salmeterol combination therapy in the prevention of exacerbations of COPD and its related effects on lung function, survival, health status, and healthcare costs.Keywords: Advair, COPD, disease exacerbation, fluticasone propionate, salmeterol, combination drug therapyhttp://www.dovepress.com/the-role-of-fluticasone-propionatesalmeterol-combination-therapy-in-pr-a4535 |
| spellingShingle | Barbara P Yawn Ibrahim Raphiou Judith S Hurley et al The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD International Journal of COPD |
| title | The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD |
| title_full | The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD |
| title_fullStr | The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD |
| title_full_unstemmed | The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD |
| title_short | The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD |
| title_sort | role of fluticasone propionate salmeterol combination therapy in preventing exacerbations of copd |
| url | http://www.dovepress.com/the-role-of-fluticasone-propionatesalmeterol-combination-therapy-in-pr-a4535 |
| work_keys_str_mv | AT barbarapyawn theroleoffluticasonepropionatesalmeterolcombinationtherapyinpreventingexacerbationsofcopd AT ibrahimraphiou theroleoffluticasonepropionatesalmeterolcombinationtherapyinpreventingexacerbationsofcopd AT judithshurley theroleoffluticasonepropionatesalmeterolcombinationtherapyinpreventingexacerbationsofcopd AT etal theroleoffluticasonepropionatesalmeterolcombinationtherapyinpreventingexacerbationsofcopd AT barbarapyawn roleoffluticasonepropionatesalmeterolcombinationtherapyinpreventingexacerbationsofcopd AT ibrahimraphiou roleoffluticasonepropionatesalmeterolcombinationtherapyinpreventingexacerbationsofcopd AT judithshurley roleoffluticasonepropionatesalmeterolcombinationtherapyinpreventingexacerbationsofcopd AT etal roleoffluticasonepropionatesalmeterolcombinationtherapyinpreventingexacerbationsofcopd |